rofecoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
selective cyclo-oxygenase inhibitors 2397 162011-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rofecoxib
  • vioxx
  • ceeoxx
a sulfonylphenyl furanone; withdrawn out of concern for TOXICITY
  • Molecular weight: 314.36
  • Formula: C17H14O4S
  • CLOGP: 1.80
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 60.44
  • ALOGS: -4.47
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.65 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 20, 1999 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 566.91 38.31 293 3212 310394 63175123
Oesophageal spasm 172.83 38.31 39 3466 3084 63482433
Oesophageal pain 166.23 38.31 39 3466 3662 63481855
Stress 161.05 38.31 77 3428 67090 63418427
Lymphoedema 121.81 38.31 39 3466 11653 63473864
Sleep apnoea syndrome 96.87 38.31 42 3463 29091 63456426
Tinnitus 91.85 38.31 43 3462 35585 63449932
Anaphylactic reaction 77.03 38.31 47 3458 66053 63419464
Drug ineffective 72.18 38.31 169 3336 1044596 62440921
Nasopharyngitis 72.14 38.31 79 3426 254178 63231339
Cystitis 71.60 38.31 42 3463 54949 63430568
Spinal cord infection 68.86 38.31 14 3491 671 63484846
Hallucination 66.48 38.31 40 3465 54777 63430740
Fluid retention 65.87 38.31 41 3464 59645 63425872
Agitation 60.81 38.31 39 3466 59718 63425799
Drug intolerance 58.23 38.31 78 3427 308583 63176934
Bronchitis 54.23 38.31 49 3456 124886 63360631
Vision blurred 54.17 38.31 43 3462 91881 63393636
Fibromyalgia 52.55 38.31 40 3465 80380 63405137
Myocardial infarction 46.95 38.31 41 3464 99852 63385665
Hyperhidrosis 46.20 38.31 42 3463 107794 63377723
Migraine 45.74 38.31 41 3464 103305 63382212
Hepatic fibrosis 45.60 38.31 14 3491 3638 63481879
Bone erosion 44.44 38.31 21 3484 17696 63467821
Impaired work ability 41.65 38.31 20 3485 17455 63468062
Feeling abnormal 38.34 38.31 44 3461 148348 63337169

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acne cystic 254.43 55.76 37 937 477 34955480
Abdominal discomfort 99.31 55.76 43 931 59792 34896165
Ankylosing spondylitis 82.31 55.76 21 953 5583 34950374
Drug intolerance 80.17 55.76 37 937 59533 34896424
Insomnia 79.51 55.76 44 930 103863 34852094
Sacroiliitis 73.42 55.76 15 959 1483 34954474
Drug ineffective 70.99 55.76 74 900 456677 34499280

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 460.88 47.83 233 3216 298683 79442256
Oesophageal spasm 195.21 47.83 42 3407 3414 79737525
Oesophageal pain 186.28 47.83 42 3407 4237 79736702
Stress 163.38 47.83 76 3373 79536 79661403
Lymphoedema 141.89 47.83 42 3407 12371 79728568
Sleep apnoea syndrome 111.01 47.83 46 3403 36432 79704507
Nasopharyngitis 104.90 47.83 87 3362 253794 79487145
Tinnitus 92.90 47.83 43 3406 44290 79696649
Drug ineffective 89.34 47.83 163 3286 1080750 78660189
Cystitis 82.86 47.83 42 3407 52690 79688249
Anaphylactic reaction 77.36 47.83 47 3402 83696 79657243
Fibromyalgia 75.00 47.83 42 3407 64298 79676641
Fluid retention 74.47 47.83 43 3406 69766 79671173
Hallucination 68.78 47.83 44 3405 85701 79655238
Migraine 67.97 47.83 44 3405 87449 79653490
Drug intolerance 65.19 47.83 68 3381 264051 79476888
Bronchitis 64.95 47.83 50 3399 130594 79610345
Agitation 60.42 47.83 43 3406 99672 79641267
Vision blurred 60.36 47.83 44 3405 105854 79635085
Ankylosing spondylitis 56.94 47.83 21 3428 12184 79728755
Myocardial infarction 53.82 47.83 52 3397 184077 79556862
Depression 53.78 47.83 56 3393 216734 79524205
Hyperhidrosis 52.40 47.83 47 3402 151445 79589494
Anxiety 50.85 47.83 58 3391 248454 79492485
Sacroiliitis 48.59 47.83 14 3435 3740 79737199
Feeling abnormal 48.47 47.83 46 3403 159153 79581786

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AH02 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Coxibs
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:50629 COX-2 inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Migraine indication 37796009 DOID:6364
Rheumatoid arthritis indication 69896004 DOID:7148
Dysmenorrhea indication 266599000
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.77 CHEMBL
Prostaglandin E2 receptor EP2 subtype GPCR Ki 7.47 PDSP
Cytochrome c oxidase subunit 2 Enzyme IC50 5.52 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 7.92 CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 4.63 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.37 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.12 CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 4.94 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.52 CHEMBL

External reference:

IDSource
4021160 VUID
N0000148611 NUI
D00568 KEGG_DRUG
4021160 VANDF
C0762662 UMLSCUI
CHEBI:8887 CHEBI
RCX PDB_CHEM_ID
CHEMBL122 ChEMBL_ID
DB00533 DRUGBANK_ID
C116926 MESH_SUPPLEMENTAL_RECORD_UI
5090 PUBCHEM_CID
2893 IUPHAR_LIGAND_ID
7768 INN_ID
0QTW8Z7MCR UNII
232158 RXNORM
30883 MMSL
8220 MMSL
d04433 MMSL
007787 NDDF
116095002 SNOMEDCT_US
387008005 SNOMEDCT_US

Pharmaceutical products:

None